One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
One-year postapproval clinical experience with radio- 223 dilution in patients with metastatic castrate-resisting prostate cancer.